Intravenous Lidocaine Infusion in the Management of Post-operative Pain in Colorectal Patients
7 mars 2016 uppdaterad av: Children's Hospital Medical Center, Cincinnati
The purpose of this study is to determine if an intravenous lidocaine infusion (compared to placebo) intraoperatively will decrease time to return of bowel function postoperatively, decrease postoperative pain, diminish postoperative opioid requirement, minimize inflammatory markers and shorten time to discharge after colorectal surgery.
Studieöversikt
Detaljerad beskrivning
Lidocaine is an amide local anesthetic that has analgesic and anti-inflammatory properties.
Lidocaine infusion is a very useful pain medication that is underutilized to treat surgical, chronic, and cancer pain in children.
The investigators propose to examine the perioperative use of lidocaine infusion in children undergoing colorectal surgery that involves an abdominal incision.
The investigators plan to measure the following outcomes: length of stay in hospital following abdominal surgery, postoperative pain scores, cumulative morphine consumption, incidences of opioid adverse-effects: respiratory depression, sedation, nausea, vomiting, time to passage of flatus, time to first bowel movement and end-tidal Sevoflurane in operating room throughout surgery.
The following laboratory values will be measured: serial lidocaine levels of pharmacokinetics and safety levels, Pro- and anti-inflammatory cytokine measurements: IL-6, IL-8, IL-10, IL-1RA and genetic variants.
Studietyp
Interventionell
Fas
- Fas 2
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
1 år till 15 år (Barn)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- male or female children 1-15 years of age
- ASA physical status 1-3
- scheduled for colorectal surgery with abdominal incision
- scheduled for complex urology surgical case
Exclusion Criteria:
- ASA physical status > 3
- postoperative intubation planned ahead of surgery
- history of chronic use of opioid
- history of hepatic,renal, or cardiac failure
- history of organ transplant
- BMI > 30
- history of cardiac arrhythmia
- history of long QT syndrome
- history of allergic reaction to lidocaine or similar agents
- history of seizure disorder
- patient without Peripherally Inserted Central Catheter or other central access with contraindication to inhalation induction
- family history or know patient susceptibility to malignant hyperthermia
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Lidocaine
The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes.
The bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr.
The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion
|
The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump.
This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr.
The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
|
|
Placebo-jämförare: Saline
The saline will be administered over an infusion pump over 10 minutes and followed by a bolus.
The infusion will be stopped after extubation prior to leaving the operating room or after 5 hours from the start of the infusion.
|
The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump.
This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr.
The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Length of stay in hospital following abdominal surgery
Tidsram: participants will be followed for the duration of hospital stay, an average of 1 week
|
The primary outcome measure will be to monitor the length of stay in hospital following abdominal surgery.
|
participants will be followed for the duration of hospital stay, an average of 1 week
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Postoperative pain scores
Tidsram: participants will be followed post-op, average 5 days
|
Study staff will monitor patients pain every 15 minutes in the PACU and record documentation every 4 hours while on the floor.
|
participants will be followed post-op, average 5 days
|
|
Cumulative morphine consumption
Tidsram: participants will be followed post-op, average 5 days
|
Staff will document how much morphine a patient uses post-operatively after abdominal surgery.
|
participants will be followed post-op, average 5 days
|
|
Incidences of opioid adverse-effects
Tidsram: participants will be followed post-op, average 5 days
|
Study staff will monitor nursing notes for respiratory depression, sedation, nausea and vomiting
|
participants will be followed post-op, average 5 days
|
|
Time to passage of flatus and bowel movement
Tidsram: participants will be followed post-op, average 5 days
|
Study staff will review nursing notes for time of passage of flatus and first bowel movement.
|
participants will be followed post-op, average 5 days
|
|
End-tidal Sevoflurane in operating room throughout surgery
Tidsram: participants will be measured until the end of the OR case, on average 6 hours
|
participants will be measured until the end of the OR case, on average 6 hours
|
|
|
Serial lidocaine levels for pharmacokinetics and safety levels
Tidsram: participants will be measured until the end of the OR case, on average 6 hours and 24 hours post-operatively
|
2 samples will be drawn at time of baseline IV placement Blood draw 0-3 minutes after bolus is complete Blood draw 9-15 minutes after the bolus is complete 2 blood samples will be drawn at the end of continuous infusion (either at end of surgery after extubation prior to leaving OR or after 5 hours from the start of the infusion) Blood draw 1 hour following the infusion Blood draw 2-3 hours following the end of the infusion 2 blood samples will be drawn 24 hours after surgery dependent of necessary labs
|
participants will be measured until the end of the OR case, on average 6 hours and 24 hours post-operatively
|
|
Pro- and anti-inflammatory cytokine measurements: IL-6, IL-8, IL-10, IL-1RA
Tidsram: participants will be measured until the end of the OR case, on average 6 hours and 24 hours post-operatively
|
2 samples will be drawn at time of baseline IV placement Blood draw 0-3 minutes after bolus is complete Blood draw 9-15 minutes after the bolus is complete 2 blood samples will be drawn at the end of continuous infusion (either at end of surgery after extubation prior to leaving OR or after 5 hours from the start of the infusion) Blood draw 1 hour following the infusion Blood draw 2-3 hours following the end of the infusion 2 blood samples will be drawn 24 hours after surgery dependent of necessary labs
|
participants will be measured until the end of the OR case, on average 6 hours and 24 hours post-operatively
|
|
Genetic variants
Tidsram: participants will be measured until the end of the OR case, on average 6 hours and 24 hours post-operatively
|
2 samples will be drawn at time of baseline IV placement Blood draw 0-3 minutes after bolus is complete Blood draw 9-15 minutes after the bolus is complete 2 blood samples will be drawn at the end of continuous infusion (either at end of surgery after extubation prior to leaving OR or after 5 hours from the start of the infusion) Blood draw 1 hour following the infusion Blood draw 2-3 hours following the end of the infusion 2 blood samples will be drawn 24 hours after surgery dependent of necessary labs
|
participants will be measured until the end of the OR case, on average 6 hours and 24 hours post-operatively
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Utredare
- Huvudutredare: Smokey J Clay, MD, Children's Hospital Medical Center, Cincinnati
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- Kuo CP, Jao SW, Chen KM, Wong CS, Yeh CC, Sheen MJ, Wu CT. Comparison of the effects of thoracic epidural analgesia and i.v. infusion with lidocaine on cytokine response, postoperative pain and bowel function in patients undergoing colonic surgery. Br J Anaesth. 2006 Nov;97(5):640-6. doi: 10.1093/bja/ael217. Epub 2006 Sep 4.
- Harvey KP, Adair JD, Isho M, Robinson R. Can intravenous lidocaine decrease postsurgical ileus and shorten hospital stay in elective bowel surgery? A pilot study and literature review. Am J Surg. 2009 Aug;198(2):231-6. doi: 10.1016/j.amjsurg.2008.10.015. Epub 2009 Mar 12.
- Duedahl TH, Hansen EH. A qualitative systematic review of morphine treatment in children with postoperative pain. Paediatr Anaesth. 2007 Aug;17(8):756-74. doi: 10.1111/j.1460-9592.2007.02213.x.
- Kain ZN, Mayes LC, Caldwell-Andrews AA, Karas DE, McClain BC. Preoperative anxiety, postoperative pain, and behavioral recovery in young children undergoing surgery. Pediatrics. 2006 Aug;118(2):651-8. doi: 10.1542/peds.2005-2920.
- Bulloch B, Tenenbein M. Validation of 2 pain scales for use in the pediatric emergency department. Pediatrics. 2002 Sep;110(3):e33. doi: 10.1542/peds.110.3.e33.
- Groudine SB, Fisher HA, Kaufman RP Jr, Patel MK, Wilkins LJ, Mehta SA, Lumb PD. Intravenous lidocaine speeds the return of bowel function, decreases postoperative pain, and shortens hospital stay in patients undergoing radical retropubic prostatectomy. Anesth Analg. 1998 Feb;86(2):235-9. doi: 10.1097/00000539-199802000-00003.
- Ash-Bernal R, Wise R, Wright SM. Acquired methemoglobinemia: a retrospective series of 138 cases at 2 teaching hospitals. Medicine (Baltimore). 2004 Sep;83(5):265-273. doi: 10.1097/01.md.0000141096.00377.3f.
- McGrath PA, Seifert CE, Speechley KN, Booth JC, Stitt L, Gibson MC. A new analogue scale for assessing children's pain: an initial validation study. Pain. 1996 Mar;64(3):435-443. doi: 10.1016/0304-3959(95)00171-9.
- Kaba A, Laurent SR, Detroz BJ, Sessler DI, Durieux ME, Lamy ML, Joris JL. Intravenous lidocaine infusion facilitates acute rehabilitation after laparoscopic colectomy. Anesthesiology. 2007 Jan;106(1):11-8; discussion 5-6. doi: 10.1097/00000542-200701000-00007.
- Candiotti KA, Yang Z, Morris R, Yang J, Crescimone NA, Sanchez GC, Bird V, Leveillee R, Rodriguez Y, Liu H, Zhang YD, Bethea JR, Gitlin MC. Polymorphism in the interleukin-1 receptor antagonist gene is associated with serum interleukin-1 receptor antagonist concentrations and postoperative opioid consumption. Anesthesiology. 2011 May;114(5):1162-8. doi: 10.1097/ALN.0b013e318216e9cb.
- Yardeni IZ, Beilin B, Mayburd E, Levinson Y, Bessler H. The effect of perioperative intravenous lidocaine on postoperative pain and immune function. Anesth Analg. 2009 Nov;109(5):1464-9. doi: 10.1213/ANE.0b013e3181bab1bd.
- Annabi EH, Barker SJ. Severe methemoglobinemia detected by pulse oximetry. Anesth Analg. 2009 Mar;108(3):898-9. doi: 10.1213/ane.0b013e318172af73.
- LUND PC, CWIK JC. PROPITOCAINE (CITANEST) AND METHEMOGLOBINEMIA. Anesthesiology. 1965 Jul-Aug;26:569-71. doi: 10.1097/00000542-196507000-00020. No abstract available.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 januari 2015
Primärt slutförande (Förväntat)
1 mars 2018
Avslutad studie (Förväntat)
1 april 2018
Studieregistreringsdatum
Först inskickad
8 april 2013
Först inskickad som uppfyllde QC-kriterierna
17 april 2013
Första postat (Uppskatta)
22 april 2013
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
8 mars 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
7 mars 2016
Senast verifierad
1 mars 2016
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Postoperativa komplikationer
- Smärta
- Neurologiska manifestationer
- Smärta, postoperativt
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Medel mot arytmi
- Depressiva medel i centrala nervsystemet
- Agenter från det perifera nervsystemet
- Sensoriska systemagenter
- Bedövningsmedel
- Membrantransportmodulatorer
- Anestesimedel, lokal
- Spänningsstyrda natriumkanalblockerare
- Natriumkanalblockerare
- Lidokain
Andra studie-ID-nummer
- CCHMC 2012-0674
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .